What do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance?

dc.contributor.authorWang, Wei‐Kang
dc.contributor.authorLu, Wen‐Min
dc.contributor.authorKweh, Qian Long
dc.contributor.authorTruong, Hoang Tu Nhi
dc.date.accessioned2020-02-25T14:18:16Z
dc.date.available2020-02-25T14:18:16Z
dc.date.copyright2020
dc.date.issued2020
dc.descriptionThis article is not available at CUD collection. The version of scholarly record of this Article is published in JManagerial and Decision Economics (2020), available online at: https://doi.org/10.1002/mde.3135.en_US
dc.description.abstractThis paper investigates how patents and research and development (R&D) spikes affect the corporate performance of 863 firm-year observations of U.S. biopharmaceutical companies. First, a dynamic data envelopment analysis model is adopted to evaluate the performance of the U.S. biopharmaceutical companies. Then, ordinary least squares regression is used to explore the effects of three patent-related variables (patent counts, citations, and claims) and R&D spikes on corporate performance. This study finds positive impacts of patent counts, citations, and claims on corporate performance. In addition, the results show that R&D spikes have negative contemporaneous effects and time-lagged effects on corporate performance. © 2020 John Wiley & Sons, Ltd.en_US
dc.identifier.citationWang, W., Lu, W., Kweh, Q.L. & Truong, H.T.N. (2020). What do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance? Managerial and Decision Economics. https://doi.org/10.1002/mde.3135en_US
dc.identifier.issn01436570
dc.identifier.urihttp://hdl.handle.net/20.500.12519/164
dc.identifier.urihttps://doi.org/10.1002/mde.3135
dc.language.isoenen_US
dc.publisherJohn Wiley and Sons Ltden_US
dc.relationAuthors Affiliations: Department of Accounting, Yuan Ze University, Taoyuan City, Taiwan; Department of International Business Administration, Chinese Culture University, Taipei, Taiwan; Faculty of Management, Canadian University Dubai, Dubai, United Arab Emirates
dc.rightsLicense to reuse the abstract has been secured from John Wiley and Sons and Copyright Clearance Center.
dc.rights.holderCopyright : 2020 John Wiley & Sons, Ltd.
dc.rights.licenseLicense Number: 5241360258934 License date: Feb 03, 2022
dc.rights.urihttps://s100.copyright.com/CustomerAdmin/PLF.jsp?ref=e4b412f6-6c72-409d-89b6-c7864bbab19d
dc.subjectIntellectual Property-Rightsen_US
dc.subjectMarket Valueen_US
dc.subjectOperating Performanceen_US
dc.subjectContextual Variables
dc.subjectFirm Value
dc.subjectInnovation
dc.subjectEfficiency
dc.subjectProductivity
dc.subjectInvestment
dc.subjectImpact
dc.titleWhat do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance?en_US
dc.typeArticleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: